CRISPR based editing of SIV proviral DNA in ART treated non-human primates.
basic_science · Level V
Where this comes from
- Record sourced from PubMed, PMID 33247091.
- Also identified by DOI 10.1038/s41467-020-19821-7 and PMC identifier 7695718.
- Licence recorded as CC BY.
- The licence permits redistribution, so the abstract is shown in full and the full text is available from the publisher.
Abstract
Elimination of HIV DNA from infected individuals remains a challenge in medicine. Here, we demonstrate that intravenous inoculation of SIV-infected macaques, a well-accepted non-human primate model of HIV infection, with adeno-associated virus 9 (AAV9)-CRISPR/Cas9 gene editing construct designed for eliminating proviral SIV DNA, leads to broad distribution of editing molecules and precise cleavage and removal of fragments of the integrated proviral DNA from the genome of infected blood cells and tissues known to be viral reservoirs including lymph nodes, spleen, bone marrow, and brain among others. Accordingly, AAV9-CRISPR treatment results in a reduction in the percent of proviral DNA in blood and tissues. These proof-of-concept observations offer a promising step toward the elimination of HIV reservoirs in the clinic.
Medical subject headings
- Anti-Retroviral Agents
- CRISPR-Cas Systems
- DNA, Viral
- Gene Editing
- Proviruses
- Simian Immunodeficiency Virus